Nantahala Capital, a private equity firm, led a $60m investment in Soleno Therapeutics, a clinical-stage biopharmaceutical company, with participation from Abingworth and Vivo Capital. “This commitment from top-tier investors is a significant demonstration of confidence ahead of expected data from the randomized withdrawal period of Study C602 in mid-2023. It strengthens our balance sheet both near and longer term and supports continued preparation for our planned New Drug Application submission, as well as the acceleration of commercial readiness activities. In addition, we are pleased to report that the rate of enrollment in the study at our US sites is progressing in line with our expectations. We anticipate initiating our UK sites shortly, which depends on the timing of local regulatory and ethics processes," Anish Bhatnagar, Soleno Therapeutics MD, Chief Executive Officer.